drugset / Trial / NCT01484171
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
Phase 3
Unknown
50 enrolled
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the antitumor efficacy and toxicity of Idarubicin and cytarabine in combination with or not with infusions of granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells in patients with newly diagnosed high-risk acute myeloid leukemia (AML).
Timeline
- Start
- 2011-08
- Primary completion
- 2017-08
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLA-mismatched donor peripheral blood stem cells | Unknown | — | — |
| Comparator | Idarubicin | Small molecule | 10 mg/m2 | — |
| Comparator | Idarubicin | Small molecule | 12 mg/m2 | — |